AI Consensus Investment Thesis
Hims & Hers Health (HIMS) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
PARTIAL SELL$27
-2.1%5-Year
NEUTRAL$39
+38.9%Latest flagship insight
Digital Health Platform Transformation Faces Critical Margin And Regulatory Headwinds
A dense synthesis reveals high consensus that transitioning from compounded peptides to authorized branded distribution permanently resets gross margins near sixty-four percent. While international scale and proprietary multi-condition subscriptions support top-line expansion, persistent marketing costs and regulatory scrutiny bound equity re-rating to specialty distributor economics.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist), Warren Buffett (Value Purist), J.P. Morgan (Titan), Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Hims & Hers Health at the forecast anchor (2026-09-18): $13,891 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 27.19 | -2.85% | -2.85% | Third-quarter financial disclosures confirm persistent GAAP net losses as marketing acquisition spending stays elevated and gross margins compress near sixty-four percent, prompting modest institutional multiple derating under restrictive monetary policy conditions. |
| Q1 2027 | 27.10 | -0.35% | -3.19% | Full-year reporting separates non-recurring legal and restructuring costs from core operating expenses. Modest top-line expansion across international acquisitions stabilizes sentiment, though ongoing convertible debt overhang limits immediate valuation upside. |
| Q2 2027 | 27.44 | +1.26% | -1.97% | Cash settlement of initial deferred acquisition installments eases dilution concerns. Seasonal demand in core dermatology and sexual health therapies lifts gross profit dollars, offsetting continued margin softness in branded weight loss. |
| Q3 2027 | 27.41 | -0.10% | -2.08% | Headline scrutiny surrounding consumer regulatory inquiries into recurring billing practices elevates risk premiums. Domestic organic growth moderation counterbalances international subscription momentum, producing temporary range-bound share price consolidation. |
| Q4 2027 | 28.18 | +2.80% | +0.67% | Regulatory clarity and stabilizing gross margins near sixty-five percent restore investor confidence. Overhead absorption from automated fulfillment infrastructure begins narrowing quarterly GAAP operating losses, generating selective institutional accumulation. |
| Q1 2028 | 28.65 | +1.70% | +2.37% | Year-end disclosures highlight positive operating cash flow and accelerating international revenue contributions. Multi-condition subscription bundles demonstrate reduced customer churn, validating management's cross-selling strategy across mature cohorts. |
| Q2 2028 | 29.27 | +2.15% | +4.58% | Deployment of automated clinical workflow tools lowers administrative overhead per consultation, driving sequential operating leverage. Core personalized wellness offerings expand, insulating gross profits from third-party wholesale drug pricing pressures. |
| Q3 2028 | 29.59 | +1.09% | +5.71% | Intensifying digital marketing competition across telehealth channels elevates customer acquisition outlays. Management exercises spending discipline, moderating subscriber intake velocity to defend positive operating margins, causing mild trading consolidation. |
| Q4 2028 | 30.48 | +3.00% | +8.88% | First sustained quarter of GAAP operating profitability arrives as vertical pharmacy automation achieves scale efficiencies. Strong year-end subscriber retention across non-weight-loss categories sparks constructive valuation multiple re-expansion. |
| Q1 2029 | 31.31 | +2.74% | +11.87% | Annual financial results establish a durable earnings foundation, with international operations achieving standalone operating breakeven. Diversified geographical revenue buffers domestic regulatory exposure, supporting gradual equity appreciation. |
| Q2 2029 | 32.31 | +3.17% | +15.42% | Early foreign patent expirations on initial GLP-1 formulations enable lower-cost generic distribution across select international markets. Expanding overseas gross margins partially counteract mature domestic revenue growth trends. |
| Q3 2029 | 32.34 | +0.10% | +15.53% | Market scrutiny shifts toward the looming 2030 convertible note maturity. Institutional investors apply a temporary liquidity discount, awaiting definitive execution details regarding cash redemption versus potential refinancing frameworks. |
| Q4 2029 | 33.26 | +2.87% | +18.84% | Management presents a viable debt retirement strategy supported by accumulated cash balances and consistent operational free cash flow. Multi-category subscriber retention remains resilient, lifting the holding discount. |
| Q1 2030 | 34.05 | +2.37% | +21.66% | Orderly cash settlement and refinancing arrangements for maturing convertible obligations eliminate default fears. Removing the primary balance sheet uncertainty drives an institutional relief rally across public shares. |
| Q2 2030 | 35.21 | +3.40% | +25.79% | Post-refinancing capital structure clarity allows expanding free cash flow to drop cleanly to net income. Automated dispensing hubs achieve target throughput, driving gross margins toward sixty-six percent. |
| Q3 2030 | 35.93 | +2.05% | +28.37% | Subscriber totals across North America, Europe, and Australia surpass mature scale thresholds. Predictable subscription cash conversion attracts value-oriented healthcare funds, establishing a firm valuation floor. |
| Q4 2030 | 36.51 | +1.60% | +30.42% | Consistent free cash flow generation prompts board authorization of an opportunistic share repurchase program. Capital returns mitigate historic equity compensation dilution, enhancing per-share earnings visibility. |
| Q1 2031 | 37.46 | +2.61% | +33.83% | Full-year audited disclosures confirm mature specialty distributor economics, generating sustainable mid-single-digit net profit margins. Institutional consensus underwrites valuation on established price-to-earnings metrics rather than speculative sales multiples. |
| Q2 2031 | 38.18 | +1.91% | +36.39% | Expansion into preventative diagnostic biomarkers and personalized hormonal health supports modest organic subscriber growth. Established brand affinity keeps customer acquisition costs contained across legacy wellness verticals. |
| Q3 2031 | 38.88 | +1.85% | +38.91% | The five-year forecast horizon concludes with the business fully transitioned into a diversified consumer healthcare enterprise. Realigned distribution margins and steady free cash generation confirm intrinsic fair valuation. |
The base-case investment thesis captures a structural transition from high-margin regulatory compounding arbitrage toward an enterprise-grade digital healthcare distributor. While top-line scale expands toward five billion dollars by 2031, consolidated gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry have permanently compressed from peak eighty percent levels to roughly sixty-four percent. Branded pharmaceutical agreements eliminate existential litigation risks but subordinate unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry to manufacturer wholesale pricing, while marketing customer acquisition expenses remain structurally elevated across digital advertising channels. Valuation sensitivity remains acutely tied to cash flow conversion and balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry rather than headline sales growth. Carrying over one billion dollars in convertible notes and substantial deferred acquisition liabilities in a restrictive interest rate environment limits capital flexibility until sustainable GAAP profitabilitygaap profitabilityGAAP profitability refers to earnings that remain positive under generally accepted accounting principles, including standard operating and noncash expense recognition.View full glossary entry emerges in late 2028.
Key insights
- Branded drug distribution permanently shifts economic surplus to pharmaceutical originators, capping long-term gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry recovery below sixty-seven percent.
- Core non-weight-loss subscriptions in dermatology and sexual health generate sticky recurring cash flows, preventing catastrophic downside valuation scenarios.
- Equity appreciation requires transition from speculative revenue multiples to cash-flow-driven valuation, governed by automated fulfillment cost absorption.
The company is shifting from selling customized compounded weight-loss treatments to distributing authentic brand-name medications. While overall sales continue to rise and the business is expanding into international markets, profits have taken a significant hit. Distributing branded drugs from major pharmaceutical companies means paying higher wholesale costs, which substantially lowers profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry compared to earlier years. Success now depends on cutting operational costs through automated pharmacies and growing its traditional subscriptions for hair loss, skincare, and sexual wellness.
Key insights
- Distributing brand-name weight-loss drugs generates high sales volume but leaves much smaller profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry.
- A loyal subscriber base in everyday wellness products provides steady cash to help fund business changes.
- Significant debt and regulatory reviews mean future stock gains depend strictly on proving genuine cash profitability.
Deep Dive
Outside market sentiment remains divided between treating the company as an embattled, ex-growth compounding casualty and viewing it as a hypergrowth digital disruptor. Sell-side consensus anchors heavily on top-line revenue expansion and non-GAAP adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry adjustments, casually treating recent GAAP net losses as transient integration friction while presuming international rollups and branded drug distribution will effortlessly restore historic double-digit operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Outside market sentiment remains divided between treating the company as an embattled, ex-growth compounding casualty and viewing it as a hypergrowth digital disruptor. Sell-side consensus anchors heavily on top-line revenue expansion and non-GAAP adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry adjustments, casually treating recent GAAP net losses as transient integration friction while presuming international rollups and branded drug distribution will effortlessly restore historic double-digit operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd overestimates the near-term durability of operating earnings by conflating distributor revenue expansion with high-margin software scalability. The market's blind spot lies in treating branded drug distribution as margin-neutral volume, ignoring that gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry have decayed twelve percentage points to sixty-four percent while customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry and debt obligations escalate. However, extreme bears overlook the resilient, high-margin non-GLP subscription core, leaving equity fairly priced for specialty distribution rather than tech-platform hypergrowth.
Repricing Catalyst
What could make the market recognize and close that gap? The decisive convergence catalyst will be consecutive audited financial releases through 2027 demonstrating whether GAAP operating breakeven and positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry resume following international integration. Observable gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry stabilization above sixty-five percent alongside marketing expense rationalization will dismantle both the hypergrowth platform fantasy and the bankruptcy collapse narrative, forcing institutional repricing toward specialized distribution fundamentals.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Stabilization
Sentiment exhibits tension between growth advocates highlighting global revenue scaling and value skeptics fixated on balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry leverage and gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry erosion. This disagreement creates high near-term volatility, deferring decisive multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry until GAAP profitabilitygaap profitabilityGAAP profitability refers to earnings that remain positive under generally accepted accounting principles, including standard operating and noncash expense recognition.View full glossary entry confirms operational stabilization.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of restrictive central bank policy rates near four percent and ten-year yields near five percent is a clear headwind. Elevated hurdle rates penalize GAAP-unprofitable growth companies carrying convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry obligations, while cumulative household inflation strains discretionary consumer budgets for out-of-pocket, non-reimbursed digital healthcare subscriptions.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across reports centers on whether the gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry collapse to sixty-four percent represents a permanent structural ceiling or a temporary transition trough. Bullish views argue that vertical automation and international generic sourcing will restore above seventy percent, justifying tech-platform multiples. Bearish perspectives contend that reselling branded pharmaceuticals permanently traps the business in low-margin specialty distribution, where advertising costs continuously exceed owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry. This debate will be resolved by observing whether gross profit per subscriber expands faster than customer acquisition spending over upcoming reporting quarters.
Base-Case Forces
Event Risk ScoreHigh75/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multi-category subscription bundling and retention | Competitive Positioning | +24% | +32% | Evidence indicates the company is expanding beyond single-condition treatments into multi-condition personalized subscriptions across dermatology, sexual health, and mental wellness. Cross-selling customized formulations deepens consumer lock-in, lowering blended churn and lifting average revenue per useraverage revenue per userAverage revenue per user (ARPU) measures the revenue generated per customer, subscriber, or account over a specified period.View full glossary entry. This annuity-like cash flow insulates platform economics from cyclical consumer volatility. |
| International footprint expansion via acquisitions | Sector And Industry | +20% | +26% | Cross-border acquisitions across the United Kingdom, Australia, and Europe establish an integrated international digital health infrastructure. Geographic diversification reduces reliance on the domestic market and mitigates US regulatory exposure. Foreign territories unlock large addressable patient populations, supporting top-line momentum and enabling future sourcing of authorized off-patent generic alternatives. |
| Vertical pharmacy automation and fulfillment efficiency | Operational Efficiency | +18% | +24% | Investments in automated dispensing hubs and specialized pharmacy facilities are beginning to normalize operational throughput. Internalizing fulfillment infrastructure lowers packaging and dispensing expenses per order, building unit cost advantages as prescription volume scales. These operational efficienciesoperational efficienciesImprovements that increase output, quality, speed, or service while using fewer resources or lowering cost.View full glossary entry protect gross processing spreads, driving incremental operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry across the forecast horizon. |
| Authorized branded pharmaceutical distribution normalization | Innovation And Product | +16% | +20% | Securing commercial distribution agreements with primary drug manufacturers for authentic branded weight-loss therapies legitimizes the platform within the regulated pharmaceutical supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry. While gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry compress toward wholesale tiers, direct supply agreements eliminate existential patent litigation risks and preserve massive captive patient traffic across core digital channels. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Structural gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry from branded distribution | Competitive Positioning | -24% | -32% | Transitioning from proprietary compounded formulations to reselling branded therapies fundamentally impairs unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry, compressing gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry from historical eighty percent peaks to sixty-four percent. Pharmaceutical originators capture the economic surplus, reducing the platform to a distribution channel and permanently capping terminal operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry below historical management targets. |
| Customer acquisition marketing cost inflation | Operational Efficiency | -18% | -24% | Direct-to-consumer digital advertising channels exhibit saturation, driving customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry higher across core social surfaces. Elevating promotional spending to counter subscriber churn traps the business on an aggressive marketing treadmill. When customer acquisition expenses outpace gross profit generation, operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry evaporates and net profitability remains constrained. |
| Convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry obligations and deferred consideration liabilities | Capital Allocation | -15% | -14% | The capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry carries over one billion dollars in zero-coupon convertible senior notes alongside hundreds of millions in deferred acquisition consideration. In an elevated interest rate regimeinterest rate regimeA persistent pattern in policy rates and market yields that shapes borrowing costs, discount rates, and asset values.View full glossary entry, approaching debt maturities and potential share issuance caps equity appreciation, creating a persistent valuation overhang and restricting discretionary capital returncapital returnCash or value distributed to investors, commonly through dividends, share repurchases, or return-of-capital payments.View full glossary entry programs. |
| Federal regulatory compliance and billing scrutiny | Regulatory | -14% | -18% | Ongoing investigations by consumer protection and healthcare regulators regarding recurring subscription billing, cancellation workflows, and asynchronous clinical prescribing impose heavy legal contingencies. Enforced workflow alterations risk lowering platform onboarding conversion rates, elevating administrative compliance overhead and subjecting the business model to an ongoing regulatory valuation discount. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Comprehensive federal compounding prohibition and enforcement | 34% | -42% | Coordinated administrative action by federal authorities terminating commercial-scale individualized compounding of active peptide analogues would eliminate customized combination therapies. The ensuing revenue loss and fixed facility write-downs would widen GAAP operating deficits, triggering severe multiple derating. Probability is assessed at thirty-four percent given continuing regulatory policy tightening surrounding compounded specialty medications. |
| Refinancing distress and dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry restructuring | 26% | -38% | Should negative operating cash flows persist under elevated interest rates while convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry maturities and deferred acquisition liabilities mature in 2030, management could be forced into emergency dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry financing. Restructuring under distressed market conditions would severely dilute common equity holders. Probability is pegged at twenty-six percent given existing liquid cash reserves. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Commercial payer enterprise formulary integration | 26% | +45% | A major commercial health insurer or pharmacy benefit manager establishing direct in-network coverage for personalized chronic care programs by 2028 would eliminate cash-pay friction. Securing enterprise coverage would slash customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry and double subscriber retention, expanding operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward fifteen percent. Conservative payer procurement cycles keep probability below thirty percent. |
| International off-patent generic semaglutide distribution | 28% | +42% | Patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry across non-US jurisdictions like Canada and Europe could enable distribution of authorized generic GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry therapies through acquired international networks by 2029. Sourcing cheap generic molecules abroad would bypass domestic patent barriers, restoring foreign gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above seventy percent. Probability remains capped at twenty-eight percent due to secondary biopharma patent litigation. |
Company Financial Analysis
Hims & Hers Health Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Recent financial results tell two conflicting stories: powerful top-line expansion alongside sudden accounting losses. Fiscal 2025 revenue surged fifty-nine percent to $2.35 billion, generating $128 million in net income. However, results reversed in early 2026, culminating in a trailing twelve-month net loss of $142 million. This earnings dislocation occurred because regulatory restrictions forced the company to stop selling lucrative compounded weight-loss drugs and start reselling brand-name therapies. While second-quarter 2026 revenue rose thirty-eight percent to $753 million, distributing branded products squeezed profit margins, proving that headline sales growth no longer guarantees immediate bottom-line cash flow.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 2.3B | USD 128.4M | USD 74M |
| 2024 | USD 1.5B | USD 126M | USD 198.3M |
| 2023 | USD 872M | USD -23.5M | USD 47M |
| 2022 | USD 526.9M | USD -65.7M | USD -33.8M |
| 2021 | USD 271.9M | USD -107.7M | USD -39.4M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 62.8x | TTM | Native | USD / USD |
| 2024 | 46.2x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profit margins have experienced an acute, structural reset. Gross profit margins declined from a peak near eighty percent in 2024 to sixty-four percent by mid-2026. This drop was directly caused by product mix changes: distributing third-party branded medicines leaves far less profit than selling in-house formulations. Consequently, operating margins fell into negative territory as digital advertising and overhead outpaced gross profits. Returning to historical eighty percent gross margins is mathematically improbable; sustainable recovery requires gross margins to level off near sixty-five percent while automated fulfillment lowers ongoing administrative expenses.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 105.6M | 4.5% | 5.5% |
| 2024 | USD 61.9M | 4.2% | 8.5% |
| 2023 | USD -29.5M | -3.4% | -2.7% |
| 2022 | USD -68.7M | -13.0% | -12.5% |
| 2021 | USD -115M | -42.3% | -39.6% |
Balance sheet and leverage
AI Review
The balance sheet has transformed from an unencumbered cash pile into a debt-laden structure. Total assets expanded to $2.15 billion by fiscal year-end 2025, but the debt-to-equity ratio rose to 2.07 following the issuance of over $1.35 billion in convertible notes. Although headline cash and short-term investments stood at $841 million in mid-2026, substantial liabilities loom behind this liquidity. Management owes hundreds of millions in deferred acquisition payments, while the convertible notes eventually require cash repayment or equity conversion, leaving little room for wasteful spending.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 1.1B | USD 577.5M | USD 892M net debt | 1.90x |
| 2024 | USD 11.3M | USD 300.3M | USD 209.2M net cash | 1.79x |
| 2023 | USD 9.9M | USD 221M | USD 86.7M net cash | 3.00x |
| 2022 | USD 5.3M | USD 179.6M | USD 41.5M net cash | 4.52x |
| 2021 | USD 5.5M | USD 247.3M | USD 66.3M net cash | 3.41x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has shifted from running a lightweight digital website to operating a capital-intensive physical business. Capital expenditures rose sharply to 9.63 percent of revenue in fiscal 2025, committing substantial cash into robotic dispensing pharmacies, automated fulfillment centers, and international company buyouts. This aggressive spending strategy aims to build proprietary fulfillment hubs that lower long-term order packaging costs. However, heavy investments have doubled annual depreciation expenses, creating a lingering accounting burden that will weigh on reported profits until order volumes expand enough to absorb the new capacity.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 226M | USD 149.3M |
| 2024 | USD 52.8M | USD 78.8M |
| 2023 | USD 26.5M | USD 48.2M |
| 2022 | USD 7.2M | USD 29.2M |
| 2021 | USD 5M | USD 22.4M |
Quarterly Forecast Scenarios
Hims & Hers Health Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $25.75 | $27.23 | $31.07 | $750.26 | |
| $22.92 | $26.74 | $32.31 | $736.44 | |
| $20.86 | $26.86 | $34.90 | $743.40 | |
| $19.18 | $26.95 | $38.39 | $755.15 | |
| $17.46 | $27.70 | $41.07 | $776.22 | |
| $16.06 | $28.15 | $44.77 | $787.13 | |
| $15.10 | $28.84 | $47.46 | $802.83 | |
| $14.34 | $29.17 | $46.51 | $812.05 | |
| $13.19 | $30.18 | $49.76 | $839.18 | |
| $12.40 | $31.09 | $53.74 | $850.50 | |
| $12.03 | $32.16 | $56.97 | $872.39 | |
| $12.27 | $32.25 | $55.26 | $885.51 | |
| $11.41 | $33.35 | $59.13 | $909.56 | |
| $11.87 | $34.20 | $62.67 | $916.13 | |
| $12.82 | $35.36 | $65.18 | $936.51 | |
| $13.20 | $36.26 | $68.44 | $947.34 | |
| $13.73 | $37.00 | $71.18 | $969.59 | |
| $14.14 | $37.93 | $73.31 | $979.99 | |
| $14.43 | $38.52 | $72.58 | $999.60 | |
| $14.71 | $39.35 | $75.48 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported common pattern confirms that while headline revenue expansion remains robust, gross margins have structurally reset from historic seventy-nine percent peaks toward sixty-four percent due to the forced transition from compounded peptides to authorized branded distribution. Correlated assumptions across bullish reports overstate the speed of margin recovery, treating wholesale distribution as software-like platform revenue while discounting deferred acquisition liabilities and convertible debt. Conversely, the strongest contrarian case identifies genuine owner-earnings decay and marketing ad-rate inflation, but overreaches by projecting insolvency, ignoring the cash-generative stability of millions of core non-weight-loss subscribers. Material unsupported claims regarding effortless twenty-percent operating margins or imminent corporate failure are discounted. Unresolved uncertainty centers on FTC subscription billing scrutiny and post-2027 international generic sourcing economics. Relative weights prioritize evidence-backed reports that anchor to verified SEC filings, balance sheet obligations, and realistic specialty distribution economics.
Universal Investor AI
The Polymath
GPT-6 AstraThis report demonstrates superior empirical discipline, incorporating primary SEC filings and earnings releases. It distinguishes top-line growth from per-share cash claims, highlighting deferred consideration liabilities and convertible principal. Its balanced valuation path reflects realistic operating leverage without relying on ungrounded multiple inflation.
Universal Investor AI
The Polymath
Opus 5Demonstrating exceptional analytical rigor with primary source attribution, this report unpacks the simultaneous raising of revenue guidance and trimming of adjusted EBITDA ceilings. It accurately details deferred acquisition liabilities, FTC regulatory investigations, and foreign off-patent generic optionality, delivering a highly objective synthesis.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashGrounding its thesis in forensic regulatory scrutiny, this analysis accurately identifies billing compliance risks, FTC investigations, and gross margin stabilization near sixty-four percent. It realistically bounds valuation within specialty distribution benchmarks, presenting an exceptionally balanced perspective on operational friction versus top-line expansion.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThis analysis provides deep factual grounding regarding international acquisition obligations, deferred consideration liabilities, and channel legitimacy following branded pharmaceutical settlements. It astutely recognizes that geographic diversification mitigates domestic policy risk, providing credible causal mechanics for mid-term gross margin stabilization.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThis report balances top-line momentum against fixed-overhead expansion and margin normalization. It accurately captures the transition costs of physical pharmacy infrastructure, though it slightly understates international acquisition contributions. The causal link between multiple compression and GAAP losses provides a sound, realistic intermediate baseline.
Universal Investor AI
The Polymath
Gemini 3.8 FlashOffering a coherent international expansion narrative, this perspective models multi-jurisdictional scale and technological triage leverage. Nevertheless, its projection of rapid EBITDA margin expansion to sixteen percent aggressively downplays marketing inflation, customer acquisition costs, and ongoing regulatory compliance overhead across foreign jurisdictions.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashFraming the company's evolution through multi-specialty subscription cross-selling and fulfillment robotics, this analysis models a viable path toward positive free cash flow. It maintains appropriate caution regarding macroeconomic tightening, although its margin recovery trajectory slightly outpaces realistic branded wholesale distribution constraints.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis view articulates how cross-border acquisitions and automated pharmacy hubs mitigate domestic regulatory vulnerability. It correctly identifies the earnings trough caused by compounding transitions, providing a robust causal bridge between fulfillment automation, unit cost absorption, and gradual GAAP earnings recovery.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProviding rigorous scrutiny of owner earnings, this view highlights the severe gross margin compression inherent in branded wholesale distribution. It properly quantifies the impending convertible note maturity, though its assumption of zero multiple expansion discounts the sticky subscriber retention exhibited across non-weight-loss therapeutic lines.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashWhile properly identifying vertical automation and brand affinity, this report relies on an overly optimistic expansion scenario. Projecting enterprise value to sixteen billion dollars assumes seamless margin recapture and flawless international execution, underestimating the persistent rent extracted by brand-name drug originators and digital advertising channels.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis analysis correctly diagnoses marketing treadmill vulnerabilities and customer churn dynamics across digital channels. Nevertheless, its projected collapse in equity value overlooks the biological stickiness of cash-pay hair loss and sexual health therapies, underestimating management's ability to rationalize customer acquisition spend to protect cash reserves.
Michael Burry AI
The Vulture
Gemini 3.8 FlashThis contrarian thesis forcefully details balance sheet leverage and commoditization risks from branded drug distribution. However, projecting structural equity value destruction below tangible book overlooks resilient cash-pay consumer demand across core dermatology, hair loss, and sexual wellness subscriptions that continue generating predictable operating cash flow.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThe report presents an incisive critique of customer acquisition treadmills and technological disintermediation. However, its extreme bear path treats the company as an unviable drop-shipper, downplaying high customer retention across customized multi-action oral formulations and the substantial revenue base established in chronic wellness.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProviding a rigorous warning on economic moat limitations, this analysis evaluates switching costs and balance sheet leverage. However, projecting prolonged multiple deflation discounts the recurring stability of the multi-million subscriber base and the tangible unit cost benefits emerging from automated pharmacy infrastructure.
Research Provenance
References & Context
This Hims & Hers Health consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 98 deduplicated sources retained for this batch.
- 01FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs | FDAfda.gov
- 02July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meetingfda.gov
- 03FTC and States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices | Federal Trade Commissionftc.gov
- 04digital, accessible format. The Hims & Hers platforms (collectively, our “platform”) include access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical records system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness.sec.gov
- 05Hims & Hers Health, Inc. - Form 10-Q - FY2026sec.gov
- 06Hims & Hers Health, Inc. - Form 8-K - FY2026sec.gov
- 07Hims & Hers Health, Inc. - Form 8-K - FY2026sec.gov
- 08Hims & Hers Health, Inc. - Form 8-K - FY2026sec.gov
- 09hims-20260630sec.gov
- 10Hims & Hers (HIMS) Q2 2026: Revenue Beats but Margins Tell a Darker Story | 24/7 Wall St.247wallst.com
- 11Hims & Hers Faces Class Action Lawsuit - HIMS | BioPharmaWatchbiopharmawatch.com
- 12Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugscnbc.com
- 13Novo Nordisk sues Hims & Hers over compounded obesity drugscnbc.com
- 14HIMS Stock Quote Price and Forecast | CNNcnn.com
- 15Hims %26 Hers Healthen.wikipedia.org
And 83 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2018-12-31–2025-12-31, 8 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.